Tropomyosin receptor kinase B (TrkB), is a receptor for brain-derived neurotrophic factor (BDNF), as well as neurotrophin-3 and -4. As such, TrkB mediates the effects of these neurotrophic factors which include neuronal differentiation and survival.

Our TrkB PAM approach is novel exciting approach for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, or Huntington’s disease with potential both as disease-modifying and symptomatic treatment. The chemical series of TrkB PAMs are in Lead generation stage.

The Addex TrkB project has received a USD 835K grant from The Michael J Fox Foundation to support the chemical exploration of our series, as well as a CHF 440K grant from the InnoSuisse supporting our collaboration with UniGE to test TrkB PAM molecules in complex models of neurodegenerative diseases.